31
January 2025 
ECO Animal Health Group
plc
("ECO" or
the "Company")
Board Changes
ECO Animal Health Group plc (AIM: EAH), a
rapidly growing global animal health company with a portfolio of
marketed veterinary products and a maturing proprietary R&D
pipeline, announces that Dr Andrew Jones, who joined the Board as a
Non-executive Director in 2017 and has served as Chairman of the
Board since 2019, has stated his intention to retire on
31st March 2025.
As part of a planned succession process, Dr
Joachim Hasenmaier joined the Board as a Non-executive Director in
February 2024 and will be appointed as Chairman of the Board of ECO
on 31st March 2025.
Dr Hasenmaier is a highly experienced
commercial leader with more than two decades in the global animal
health industry. From 2001 to 2019, he held a variety of senior
roles within the animal health division at Boehringer Ingelheim,
concluding as member of the Board of Managing Directors responsible
for the entire animal health division. During this time, he led
successful transformation initiatives including the integration of
the former Sanofi animal health business Merial, spearheaded key
product launches and supported rapid global growth and
expansion.
Dr Andrew Jones stepped down as Chairman of the
Nomination Committee on 30 January 2025 and Dr Hasenmaier was
appointed as Chairman of the Nomination Committee on the same day.
On 31 March 2025, Dr Jones will also step down from the Audit and
Remuneration Committees. There will be no further changes to
the composition of these committees.
Dr Andrew
Jones, outgoing Chairman, commented:
"It has been
a privilege to serve as Chairman of ECO Animal Health over the past
six years and to work alongside such a talented and dedicated team.
After several years as Chairman, I have decided the time is right
to retire and I'm delighted to be handing over to someone with such
a wealth of experience and expertise. Over the years, we have
expanded ECO's global reach, built a robust product portfolio, and
laid the groundwork for a strong pipeline of innovative solutions
in animal health. Joachim is absolutely the right person to succeed
me as Chair, he has a wealth of commercial industry experience and,
since joining the Board as a Non-executive Director, has
demonstrated solid leadership and expertise."
Dr Joachim
Hasenmaier, incoming Chairman, added:
"I am
honoured to be appointed Chairman of ECO Animal Health. On behalf
of the Board, I would like to thank Andrew for his exceptional
leadership, under which ECO has taken great strides in innovation,
global reach and product development. ECO is moving into its
important next phase with increased focus on the commercialisation
of its research and development pipeline. I look forward to working
with the Board and the management team to build on this momentum
and deliver value for all stakeholders."
-Ends-
For further
information please contact:
|
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
|
ICR Healthcare
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global
offices including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a
proprietary, patented medication which is effective against both
respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
